2004. Other areas of high resistance include most of the former Soviet Union countries, and several regions of China. The prevalence of drug resistance is higher in patients who have previously been treated for TB: in Uzbekistan and Azerbaijan up to 60% of cases of TB in individuals who have had prior TB treatment are MDR, an astonishingly high level of resistance with major implications for management of individual cases and national TB control. India, the origin of much TB imported into the UK, reported a prevalence of MDR-TB of 5% overall and 17.2% in previously treated cases.
Trend data were presented for a number of countries and several patterns emerged. Most countries of West or Central Europe have stable rates of resistance, and the USA reported a decline in TB notifications and rates of MDR-TB. Most TB in the USA has in the past been 'home-grown' , as previously in the UK, and with increasing immigration, this pattern is likely to change. MDR-TB rates are stabilising in Latvia and Estonia, two areas with previously high rates where there has been huge effort to bring this problem under control. However rates are continuing to increase in many parts of Russia and China. It is recognised that this survey does not cover some key areas: only six African countries provided data, which reflects the widespread lack of mycobacterial culture facilities available. Since Africa has the highest incidence of TB in the world, this is an important omission. The information that has been available has suggested low rates of drug resistance in Africa in the past, but this is clearly increasing, particularly in Southern Africa.
In addition to the rise in MDR-TB, there has been increasing concern about the global emergence of extensively drug-resistant TB (XDR-TB). 7, 8 These strains are not only resistant to rifampicin and isoniazid, but also demonstrate extensive resistance to second-line antituberculous drugs. XDR-TB has now been reported from 45 countries worldwide, although it is likely to be much more widespread because many countries do not have the facilities to detect it routinely. The major impact appears to be on resource-limited countries with high HIV prevalence, where alarmingly high and rapid mortality has been reported. 9 In recognition of this new challenge the WHO has set up a global task force on XDR-TB. Key areas for action include the expansion of laboratory facilities for mycobacterial culture and sensitivity, which will aid detection/management of individual cases and the collection of epidemiological data; action to strengthen TB control programmes to increase treatment completion rates; increased availability of second-line antituberculous agents; and strategies to reduce transmission, particularly in healthcare settings. Recent advances in the field of TB may in the future provide weapons with which to fight XDR strains, for example rapid testing for drug resistance, interferon-gamma release assays for earlier detection of active/latent disease, and strain typing methods to confirm outbreaks at an earlier stage and thus facilitate more rapid control. However, on a global level, these expensive and often technically challenging techniques are unlikely to be available in the areas that need them most for some considerable time. More immediate advances may be made through the development of new antituberculous drugs, 10 and/or an effective TB vaccine: a number of vaccine candidates are in development including MVA85A, which is currently undergoing phase 2 clinical trials. 11 In the UK, this degree of resistance is, as yet, unusual. However, the massive expense and logistical burden of treating such patients, and their contacts, necessitate advanced planning for its arrival. At the level of the individual patient, as always with TB, awareness is key, not only of the possibility of TB as a differential diagnosis in an ill patient, but also of the existence of drug resistance in different parts of the world, and the need to consider resistance as part of the initial assessment of any patient with possible TB, 3 with institution of appropriate infection control procedures including isolation in a negative pressure room.
